Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()

ARQ 087 is a multi-tyrosine kinase inhibitor with potent activity against the FGFR receptor family, currently in Phase I clinical studies for the treatment of advanced solid tumors. The compound has a very safe profile and induces tumor regressions in FGFR-driven models. The feasibility of combining...

Descripción completa

Detalles Bibliográficos
Autores principales: Chilà, Rosaria, Hall G., Terence, Abbadessa, Giovanni, Broggini, Massimo, Damia, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Short communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293737/
https://www.ncbi.nlm.nih.gov/pubmed/28161661
http://dx.doi.org/10.1016/j.tranon.2016.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293737/
https://www.ncbi.nlm.nih.gov/pubmed/28161661
http://dx.doi.org/10.1016/j.tranon.2016.12.003

Ejemplares similares